AbbVie's blockbuster hopeful Rinvoq, J&J's Spravato eye EU rollouts, thanks to new backing

Painted as the follow-up drug to megablockbuster Humira, AbbVie’s JAK med Rinvoq is already notching blockbuster forecasts from market watchers. A green light to treat European patients should give the rheumatoid arthritis med a leg up in reaching that lofty goal.